CTOs on the Move

Medica HealthCare Plans

www.medicaplans.com

 
Medica HealthCare Plans is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Elementis Specialties (RHEOX)

Elementis Specialties (RHEOX) is a Hightstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AQ Safety

AQ Safety is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tower Health

Tower Health is a regional integrated healthcare system that offers leading-edge, compassionate healthcare and wellness services to communities in Berks, Chester, Montgomery, and Philadelphia Counties. With nearly 12,000 team members, Tower Health consists of Reading Hospital in West Reading; Chestnut Hill Hospital in Philadelphia; Phoenixville Hospital in Phoenixville; Pottstown Hospital in Pottstown; and St. Christopher`s Hospital for Children, a partnership of Tower Health and Drexel University in Philadelphia. It also includes Reading Hospital Rehabilitation at Wyomissing; Reading Hospital School of Health Sciences in West Reading; home healthcare provided by Tower Health at Home; TowerDirect ambulance and emergency response; Tower Health Medical Group; and a network of 25 urgent care facilities across the Tower Health service area.

The HealthCare Chaplaincy

The HealthCare Chaplaincy Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The HealthCare Chaplaincy Inc. is based in New York, NY. You can find more information on The HealthCare Chaplaincy Inc. at www.healthcarechaplaincy.org

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.